Presentation download: Development of a recombinant protective antigen (rPA) based anthrax vaccine

download, anthrax vaccine, R&D

Thomas Fuerst, Executive Vice President, Chief Scientific Officer from PharmAthene joined us at the World Vaccine Congress 2012 in Washington to give details about the development of a recombinant protective antigen (rPA) based anthrax vaccine. In his presentation he detailed:

· Background Information – Next Generation Vaccine

· Development of a Robust Manufacturing Platform

· Analytical Methods for Purity and Characterization

· BDS and FDP Bioactivity Assays


Product Overview:

· For pre- and post-exposure protection

· Highly purified recombinant version of Protective Antigen

· Phase 1 and 2 Phase 2 clinical trials completed; >770 individuals

Target Product Profile:

· 3 dose intramuscular (IM) regimen

· Enhanced convenience (prefilled syringe) and cost-effectiveness

· Significant vaccine efficacy based on the Animal Rule


Why not download the full presentation and find out more about the development of a recombinant protective antigen (rPA) based anthrax vaccine:

· Well characterized recombinant Protective Antigen (rPA) anthrax vaccine

· Established a robust manufacturing platform at full commercial scale

· Comprehensive set of analytical assays for in process, release, and stability testing


Tell us your views on this anthrax vaccine by commenting below!

Download the full presentation here!

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *